Johnson & Johnson (NYSE:JNJ) Shares Purchased by Public Sector Pension Investment Board

Public Sector Pension Investment Board increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 470.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 524,839 shares of the company’s stock after purchasing an additional 432,800 shares during the period. Public Sector Pension Investment Board’s holdings in Johnson & Johnson were worth $85,055,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of JNJ. Strategic Wealth Partners Ltd. increased its position in shares of Johnson & Johnson by 26.7% during the 1st quarter. Strategic Wealth Partners Ltd. now owns 6,077 shares of the company’s stock worth $961,000 after purchasing an additional 1,280 shares during the last quarter. Raelipskie Partnership increased its position in shares of Johnson & Johnson by 3.9% during the first quarter. Raelipskie Partnership now owns 14,090 shares of the company’s stock valued at $2,229,000 after acquiring an additional 531 shares during the last quarter. Community Trust & Investment Co. raised its stake in shares of Johnson & Johnson by 0.9% in the 1st quarter. Community Trust & Investment Co. now owns 96,066 shares of the company’s stock valued at $15,197,000 after acquiring an additional 877 shares during the period. Cetera Investment Advisers lifted its holdings in shares of Johnson & Johnson by 224.0% in the 1st quarter. Cetera Investment Advisers now owns 707,273 shares of the company’s stock worth $111,884,000 after acquiring an additional 488,955 shares during the last quarter. Finally, Cetera Advisors LLC boosted its position in shares of Johnson & Johnson by 71.6% during the 1st quarter. Cetera Advisors LLC now owns 274,630 shares of the company’s stock worth $43,444,000 after purchasing an additional 114,547 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Royal Bank of Canada increased their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $175.94.

Johnson & Johnson Stock Up 0.6 %

Johnson & Johnson stock opened at $155.39 on Thursday. The stock has a market cap of $374.12 billion, a PE ratio of 22.49, a P/E/G ratio of 2.77 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock’s fifty day moving average is $159.52 and its two-hundred day moving average is $156.38. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.19%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.